

# Roland Seiler

## List of Publications by Citations

**Source:** <https://exaly.com/author-pdf/4085369/roland-seiler-publications-by-citations.pdf>

**Version:** 2024-04-25

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

83  
papers

2,199  
citations

23  
h-index

45  
g-index

94  
ext. papers

2,991  
ext. citations

5.2  
avg, IF

4.66  
L-index

#	Paper	IF	Citations
83	Impact of Molecular Subtypes in Muscle-invasive Bladder Cancer on Predicting Response and Survival after Neoadjuvant Chemotherapy. <i>European Urology</i> , <b>2017</b> , 72, 544-554	10.2	411
82	A Consensus Molecular Classification of Muscle-invasive Bladder Cancer. <i>European Urology</i> , <b>2020</b> , 77, 420-433	10.2	309
81	Associations of Luminal and Basal Subtyping of Prostate Cancer With Prognosis and Response to Androgen Deprivation Therapy. <i>JAMA Oncology</i> , <b>2017</b> , 3, 1663-1672	13.4	138
80	Her2 amplification is significantly more frequent in lymph node metastases from urothelial bladder cancer than in the primary tumours. <i>European Urology</i> , <b>2011</b> , 60, 350-7	10.2	106
79	Evasion of immunosurveillance by genomic alterations of PPAR $\alpha$ /RXR $\alpha$ in bladder cancer. <i>Nature Communications</i> , <b>2017</b> , 8, 103	17.4	66
78	Impact of Immune and Stromal Infiltration on Outcomes Following Bladder-Sparing Trimodality Therapy for Muscle-Invasive Bladder Cancer. <i>European Urology</i> , <b>2019</b> , 76, 59-68	10.2	63
77	Removal of limited nodal disease in patients undergoing radical prostatectomy: long-term results confirm a chance for cure. <i>Journal of Urology</i> , <b>2014</b> , 191, 1280-5	2.5	59
76	CCND1/CyclinD1 status in metastasizing bladder cancer: a prognosticator and predictor of chemotherapeutic response. <i>Modern Pathology</i> , <b>2014</b> , 27, 87-95	9.8	59
75	Her2 alterations in muscle-invasive bladder cancer: Patient selection beyond protein expression for targeted therapy. <i>Scientific Reports</i> , <b>2017</b> , 7, 42713	4.9	58
74	Divergent Biological Response to Neoadjuvant Chemotherapy in Muscle-invasive Bladder Cancer. <i>Clinical Cancer Research</i> , <b>2019</b> , 25, 5082-5093	12.9	50
73	Targeting HER2 with T-DM1, an Antibody Cytotoxic Drug Conjugate, is Effective in HER2 Over Expressing Bladder Cancer. <i>Journal of Urology</i> , <b>2015</b> , 194, 1120-31	2.5	45
72	Molecular Characterization of Neuroendocrine-like Bladder Cancer. <i>Clinical Cancer Research</i> , <b>2019</b> , 25, 3908-3920	12.9	42
71	Does Stepwise Voltage Ramping Protect the Kidney from Injury During Extracorporeal Shockwave Lithotripsy? Results of a Prospective Randomized Trial. <i>European Urology</i> , <b>2016</b> , 69, 267-73	10.2	34
70	Selective Inhibition of the Lactate Transporter MCT4 Reduces Growth of Invasive Bladder Cancer. <i>Molecular Cancer Therapeutics</i> , <b>2018</b> , 17, 2746-2755	6.1	34
69	An Oncofetal Glycosaminoglycan Modification Provides Therapeutic Access to Cisplatin-resistant Bladder Cancer. <i>European Urology</i> , <b>2017</b> , 72, 142-150	10.2	29
68	Unravelling disparate roles of NOTCH in bladder cancer. <i>Nature Reviews Urology</i> , <b>2018</b> , 15, 345-357	5.5	29
67	Tumor regression grade of urothelial bladder cancer after neoadjuvant chemotherapy: a novel and successful strategy to predict survival. <i>American Journal of Surgical Pathology</i> , <b>2014</b> , 38, 325-32	6.7	28

66	Androgen receptors are differentially expressed in Gleason patterns of prostate cancer and down-regulated in matched lymph node metastases. <i>Prostate</i> , <b>2011</b> , 71, 453-60	4.2	28
65	Low PCA3 expression is a marker of poor differentiation in localized prostate tumors: exploratory analysis from 12,076 patients. <i>Oncotarget</i> , <b>2017</b> , 8, 50804-50813	3.3	27
64	Discrepancy Between European Association of Urology Guidelines and Daily Practice in the Management of Non-muscle-invasive Bladder Cancer: Results of a European Survey. <i>European Urology Focus</i> , <b>2019</b> , 5, 681-688	5.1	26
63	Liquid Biopsy-Analysis of Circulating Tumor DNA (ctDNA) in Bladder Cancer. <i>Bladder Cancer</i> , <b>2018</b> , 4, 19-29	1	25
62	Prediction of Lymph Node Metastasis in Patients with Bladder Cancer Using Whole Transcriptome Gene Expression Signatures. <i>Journal of Urology</i> , <b>2016</b> , 196, 1036-41	2.5	24
61	FGFR3 expression in primary invasive bladder cancers and matched lymph node metastases. <i>Journal of Urology</i> , <b>2015</b> , 193, 325-30	2.5	23
60	Long non-coding RNAs identify a subset of luminal muscle-invasive bladder cancer patients with favorable prognosis. <i>Genome Medicine</i> , <b>2019</b> , 11, 60	14.4	21
59	Extracapsular extension but not the tumour burden of lymph node metastases is an independent adverse risk factor in lymph node-positive bladder cancer. <i>Histopathology</i> , <b>2011</b> , 58, 571-8	7.3	19
58	Evolution of Urothelial Bladder Cancer in the Context of Molecular Classifications. <i>International Journal of Molecular Sciences</i> , <b>2020</b> , 21,	6.3	19
57	Microhematuria assessment an IBCN consensus-Based upon a critical review of current guidelines. <i>Urologic Oncology: Seminars and Original Investigations</i> , <b>2016</b> , 34, 437-51	2.8	18
56	Pelvic lymph nodes: distribution and nodal tumour burden of urothelial bladder cancer. <i>Journal of Clinical Pathology</i> , <b>2010</b> , 63, 504-7	3.9	18
55	Prevalence and prognostic significance of TMPRSS2-ERG gene fusion in lymph node positive prostate cancers. <i>Prostate</i> , <b>2014</b> , 74, 1647-54	4.2	16
54	Neoadjuvant treatment for muscle-invasive bladder cancer: The past, the present, and the future. <i>Urologic Oncology: Seminars and Original Investigations</i> , <b>2018</b> , 36, 413-422	2.8	16
53	Morphologic and genomic characterization of urothelial to sarcomatoid transition in muscle-invasive bladder cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , <b>2019</b> , 37, 826-836 <sup>2.8</sup>	2.8	15
52	Optimization of Extracorporeal Shock Wave Lithotripsy Delivery Rates Achieves Excellent Outcomes for Ureteral Stones: Results of a Prospective Randomized Trial. <i>Journal of Urology</i> , <b>2015</b> , 194, 418-23	2.5	15
51	Assessing the quality of studies on the diagnostic accuracy of tumor markers. <i>Urologic Oncology: Seminars and Original Investigations</i> , <b>2014</b> , 32, 1051-60	2.8	15
50	MMP-2 and MMP-9 in lymph-node-positive bladder cancer. <i>Journal of Clinical Pathology</i> , <b>2011</b> , 64, 1078-82 <sup>9</sup>	3.9	15
49	Multicenter Validation of Histopathologic Tumor Regression Grade After Neoadjuvant Chemotherapy in Muscle-invasive Bladder Carcinoma. <i>American Journal of Surgical Pathology</i> , <b>2019</b> , 43, 1600-1610	6.7	15

48	alpha- and beta-adrenergic receptor mechanisms in spontaneous contractile activity of rat ileal longitudinal smooth muscle. <i>Journal of Gastrointestinal Surgery</i> , <b>2005</b> , 9, 227-35	3.3	14
47	Update of the ICUD-SIU International Consultation on Bladder Cancer 2018: urinary diversion. <i>World Journal of Urology</i> , <b>2019</b> , 37, 85-93	4	14
46	Role of selective alpha and beta adrenergic receptor mechanisms in rat jejunal longitudinal muscle contractility. <i>Journal of Gastrointestinal Surgery</i> , <b>2008</b> , 12, 1087-93	3.3	13
45	Molecular footprints of muscle-invasive bladder cancer in smoking and nonsmoking patients. <i>Urologic Oncology: Seminars and Original Investigations</i> , <b>2019</b> , 37, 818-825	2.8	13
44	Bcl-2 predicts response to neoadjuvant chemotherapy and is overexpressed in lymph node metastases of urothelial cancer of the bladder. <i>Urologic Oncology: Seminars and Original Investigations</i> , <b>2015</b> , 33, 166.e1-8	2.8	12
43	Bladder cancer cells secrete while normal bladder cells express but do not secrete AGR2. <i>Oncotarget</i> , <b>2016</b> , 7, 15747-56	3.3	12
42	Re: Aurŕie Kamoun, Aurŕien de Reyniŕ, Yves Allory, et al. A Consensus Molecular Classification of Muscle-invasive Bladder Cancer. <i>Eur Urol</i> 2020;77:420-33: A Statement from the International Bladder Cancer Network. <i>European Urology</i> , <b>2020</b> , 77, e105-e106	10.2	12
41	Distribution of Molecular Subtypes in Muscle-invasive Bladder Cancer Is Driven by Sex-specific Differences. <i>European Urology Oncology</i> , <b>2020</b> , 3, 420-423	6.7	11
40	Recent progress with next-generation biomarkers in muscle-invasive bladder cancer. <i>International Journal of Urology</i> , <b>2017</b> , 24, 7-15	2.3	10
39	Genomic Subtyping in Bladder Cancer. <i>Current Urology Reports</i> , <b>2020</b> , 21, 9	2.9	9
38	Neuroendocrine Differentiation in Metastatic Conventional Prostate Cancer Is Significantly Increased in Lymph Node Metastases Compared to the Primary Tumors. <i>International Journal of Molecular Sciences</i> , <b>2017</b> , 18,	6.3	9
37	Role of beta1-, beta2-, and beta3-adrenoceptors in contractile hypersensitivity in a model of small bowel transplantation. <i>Surgery</i> , <b>2008</b> , 143, 94-102	3.6	9
36	Validation of a neuroendocrine-like classifier confirms poor outcomes in patients with bladder cancer treated with cisplatin-based neoadjuvant chemotherapy. <i>Urologic Oncology: Seminars and Original Investigations</i> , <b>2020</b> , 38, 262-268	2.8	9
35	High CD10 expression predicts favorable outcome in surgically treated lymph node-positive bladder cancer patients. <i>Human Pathology</i> , <b>2012</b> , 43, 269-75	3.7	8
34	A Consensus Molecular Classification of Muscle-Invasive Bladder Cancer. <i>SSRN Electronic Journal</i> ,	1	8
33	Post-translational modifications in bladder cancer: Expanding the tumor target repertoire. <i>Urologic Oncology: Seminars and Original Investigations</i> , <b>2020</b> , 38, 858-866	2.8	8
32	Achieving teamwork in naturalistic sport settings: An exploratory qualitative study of informational resources supporting football players' activity when coordinating with others. <i>Psychology of Sport and Exercise</i> , <b>2018</b> , 38, 154-166	4.2	8
31	Team Cognition in Sport: How Current Insights Into How Teamwork Is Achieved in Naturalistic Settings Can Lead to Simulation Studies. <i>Frontiers in Psychology</i> , <b>2019</b> , 10, 2082	3.4	7

30	Using the neoadjuvant chemotherapy paradigm to develop precision therapy for muscle-invasive bladder cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , <b>2016</b> , 34, 469-76	2.8	7
29	A low or high BMI is a risk factor for renal hematoma after extracorporeal shock wave lithotripsy for kidney stones. <i>Urolithiasis</i> , <b>2017</b> , 45, 317-321	3.2	7
28	Forty years of cisplatin-based chemotherapy in muscle-invasive bladder cancer: are we understanding how, who and when?. <i>World Journal of Urology</i> , <b>2019</b> , 37, 1759-1765	4	7
27	Is The Cancer Genome Atlas (TCGA) bladder cancer cohort representative of invasive bladder cancer?. <i>Urologic Oncology: Seminars and Original Investigations</i> , <b>2017</b> , 35, 458.e1-458.e7	2.8	6
26	The consensus molecular classification of muscle-invasive bladder cancer		6
25	Mechanistic target of rapamycin (MTOR) protein expression in the tumor and its microenvironment correlates with more aggressive pathology at cystectomy. <i>Urologic Oncology: Seminars and Original Investigations</i> , <b>2018</b> , 36, 342.e7-342.e14	2.8	5
24	Angewandte Sportpsychologie in der Schweiz: Ausbildungskonzeption und Berufsfeldperspektiven. <i>Zeitschrift Fur Sportpsychologie</i> , <b>2009</b> , 16, 29-34	0.3	5
23	Paternally Expressed Gene 10 (PEG10) Promotes Growth, Invasion, and Survival of Bladder Cancer. <i>Molecular Cancer Therapeutics</i> , <b>2020</b> , 19, 2210-2220	6.1	5
22	Molecular Characterization of Residual Bladder Cancer after Neoadjuvant Pembrolizumab. <i>European Urology</i> , <b>2021</b> , 80, 149-159	10.2	5
21	Association of p53-ness with chemo-resistance in urothelial cancers treated with neoadjuvant gemcitabine plus cisplatin.. <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, 4512-4512	2.2	4
20	New horizons in bladder cancer research. <i>Urologic Oncology: Seminars and Original Investigations</i> , <b>2020</b> , 38, 867-885	2.8	4
19	Molecular landscape of carcinoma invading bladder muscle: does patient age matter?. <i>BJU International</i> , <b>2019</b> , 124, 719-721	5.6	3
18	Morphologic and genomic characterization of urothelial to sarcomatoid transition in muscle-invasive bladder cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , <b>2019</b> , 37, 573.e19-573.e29	2.8	3
17	The association of cigarette smoking and pathological response to neoadjuvant platinum-based chemotherapy in patients undergoing treatment for urinary bladder cancer - A prospective European multicenter observational study of the EAU Young Academic Urologists (YAU) urothelial carcinoma working group. <i>Surgical Oncology</i> , <b>2020</b> , 34, 312-317	2.5	3
16	Predicting response to neoadjuvant chemotherapy in bladder cancer: controversies remain with genomic DNA sequencing. <i>Translational Andrology and Urology</i> , <b>2016</b> , 5, 271-3	2.3	3
15	Different stages in drug development for muscle-invasive bladder cancer. <i>Translational Andrology and Urology</i> , <b>2017</b> , 6, 1060-1066	2.3	2
14	Conditional analyses of recurrence and progression in patients with TaG1 non-muscle-invasive bladder cancer. <i>Urologic Oncology: Seminars and Original Investigations</i> , <b>2018</b> , 36, 238.e19-238.e27	2.8	2
13	Robot-assisted versus open cystectomy. <i>Lancet, The</i> , <b>2018</b> , 391, 2479-2480	4.0	2

12	Pelvic lymph node dissection in the context of radical cystectomy: a thorough insight into the connection between patient, surgeon, pathologist and treating institution. <i>Research and Reports in Urology</i> , <b>2013</b> , 5, 121-8	1.3	2
11	Strukturmerkmale des Berufsfelds Sportpsychologie in der Schweiz. <i>Zeitschrift Fur Sportpsychologie</i> , <b>2018</b> , 25, 33-44	0.3	2
10	Impact of tumor size on the oncological outcome of high-grade nonmuscle invasive bladder cancer - examining the utility of classifying Ta bladder cancer based on size. <i>Urologic Oncology: Seminars and Original Investigations</i> , <b>2020</b> , 38, 851.e19-851.e25	2.8	2
9	Seminal Vesical Sparing Cystectomy for Bladder Cancer is Feasible with Good Functional Results without Impairing Oncological Outcomes: A Longitudinal Long-Term Propensity-Matched Single Center Study. <i>Journal of Urology</i> , <b>2021</b> , 205, 1629-1640	2.5	2
8	A showcase study on personalized in silico drug response prediction based on the genetic landscape of muscle invasive bladder cancer. <i>Scientific Reports</i> , <b>2021</b> , 11, 5849	4.9	1
7	Characteristics of upper urinary tract urothelial carcinoma in the context of bladder cancer: a narrative review. <i>Translational Andrology and Urology</i> , <b>2021</b> , 10, 4036-4050	2.3	1
6	Predictive models of response to neoadjuvant chemotherapy in muscle-invasive bladder cancer using nuclear morphology and tissue architecture. <i>Cell Reports Medicine</i> , <b>2021</b> , 2, 100382	18	1
5	Evaluation of carbonic anhydrase IX as a potential therapeutic target in urothelial carcinoma. <i>Urologic Oncology: Seminars and Original Investigations</i> , <b>2021</b> , 39, 498.e1-498.e11	2.8	0
4	Adjuvant Treatment of Residual Disease Following Neoadjuvant Chemotherapy and Radical Cystectomy for Muscle Invasive Bladder Cancer. <i>Bladder Cancer</i> , <b>2020</b> , 6, 525-535	1	
3	Re: Comprehensive Transcriptional Analysis of Early-Stage Urothelial Carcinoma. <i>European Urology</i> , <b>2016</b> , 70, 1076	10.2	
2	Eine Vision für die Zeitschrift für Sportpsychologie. <i>Zeitschrift Fur Sportpsychologie</i> , <b>2020</b> , 27, 13-19	0.3	
1	Re: A Clonal Expression Biomarker Associates with Lung Cancer Mortality. <i>European Urology</i> , <b>2020</b> , 78, 925-926	10.2	